Printer Friendly

Long offered abroad by Rx, OTC: a new (to the US) first-line agent for heavy menstrual bleeding: tranexamic acid has a track record of efficacy and safety in Europe. Consider it an addition to your therapeutic options.

Heavy menstrual bleeding (HMB) is a major gynecologic problem, affecting more than 30% of women at some point in their life. Evaluation of HMB can be extensive, including a history and physical exam; transvaginal ultrasonography; hysteroscopy or sonohysterography; assessment for anemia; and, when indicated, endometrial sampling. Some women who have HMB may need to be evaluated for a bleeding diathesis, such as von Willebrand disease or a platelet disorder.

Many women who have HMB have a structural abnormality of the uterus, such as a submucous fibroid or endometrial polyp. For them, surgical treatment (if the condition is amenable) typically resolves their heavy bleeding.

Others have ovulatory bleeding, but no detectable structural uterine abnormality or identifiable bleeding diathesis. In community practice, these women are typically treated with a two-step protocol:

1. medication, such as a nonsteroidal anti-inflammatory agent or a hormonal preparation (estrogen-progestin or progestin only)

2. procedure-based treatment if medical therapy is unsuccessful: insertion of a levonorgestrel-releasing intrauterine system (LNG-IUS), endometrial ablation, or hysterectomy.

Tranexamic acid (Lysteda) (FIGURE 1) is a recently approved nonhormonal treatment for HMB. It provides an additional nonhormonal option that would be used in Step I of this protocol.

How tranexamic acid produces its effect

Endometrial concentrations of tissue plasminogen activator and plasmin are elevated in women who have HMB. Tranexamic acid blocks the action of plasmin, thereby reducing fibrin degradation, stabilizing clots, and reducing menstrual bleeding (FIGURE 2, page 10). It has no effect on standard blood coagulation parameters, such as the platelet count, activated partial thromboplastin time, and prothrombin time. Tranexamic acid is eliminated, largely intact, in urine. Its terminal half-life is approximately 2 hours.

Randomized clinical trials have demonstrated that tranexamic acid is effective for HMB.

Study #1. 294 women who had HMB were randomized to one of three arms: placebo; tranexamic acid, 1,950 mg/d for 5 days each menstrual cycle; or tranexamic acid, 3,900 mg/d for the same duration. Menstrual blood loss was reduced in the three groups by 5%, 25%, and 39%, respectively. Self-reported quality of life was most improved among women who received active drug at 3,900 mg/d. (1)



Study #2. 187 women who had HMB were randomized to placebo or tranexamic acid, 3,900 mg/d, for 5 days. Menstrual blood loss was reduced by 12% in the placebo group and 38% in the group taking tranexamic acid. (2)

Notably, women who had uterine myomata were allowed to enter this trial. In a preliminary analysis (reported as an abstract), the reduction in menstrual blood loss was similar in women who did not (38%) and who did (34%) have myomata.

Dosing, adverse effects, contraindications

The FDA has approved tranexamic acid at a dosage of 1,300 mg (two 650-mg tablets) three times daily for 5 days each menstrual cycle. The medication cycle is typically initiated on the first day of menstrual bleeding. Cost of a single 5-day treatment cycle (i.e., six tablets daily for 5 days--30 650-mg tablets, total) in the United States is approximately $175.

The most common side effects reported in clinical trials were:

* headache

* sinus and nasal symptoms

* back pain

* musculoskeletal pain.

Women who have a history of venous thromboembolism (VTE) or strong risk factors for VTE should not use tranexamic acid because of concern that, by reducing fibrin degradation, the drug may increase the tendency to clot. A strong scientific link between tranexamic acid and VTE is controversial, however. In two observational studies from Sweden (where tranexamic acid is available over the counter), investigators reported no increase in VTE events associated with the drug. (3,4)

For HMB associated with a clotting disorder

Women who have von Willebrand disease or a platelet aggregation and release disorder are at increased risk of HMB. They are often prescribed intranasal desmopressin (DDAVP), to be used during menses to improve coagulation and reduce HMB.

In one head-to-head trial of DDAVP and tranexamic acid for HMB in women who had abnormal clotting, tranexamic acid (1 g, four times daily for the first 5 days of the menstrual cycle) resulted in a greater reduction in menstrual blood loss than DDAVP. (5)

Efficacy in obstetric bleeds?

In birth centers where no blood products are available, obstetric hemorrhage is a major cause of maternal death. Uterotonics, such as misoprostol and oxytocin, play a major role in helping reduce morbidity and mortality associated with OB hemorrhage, but the search has continued for additional agents to reduce the rate of maternal death from postpartum bleeding.

In two pilot studies, researchers reported that administering tranexamic acid to parturient women reduced the volume of postpartum blood loss. (6) A multi-center, randomized trial of tranexamic acid (1 g, given intravenously) to treat women who have postpartum hemorrhage is under way. (7)

Another option to consider

In many countries of Europe, tranexamic acid has been available by prescription for decades. There, its track record of efficacy and safety is good. (In some, the drug can be purchased over-the-counter.) From what clinical trials, and experience abroad, have demonstrated, tranexamic acid will be useful for treating heavy menstrual bleeding. O


(1.) Lukes A, Waldbaum A, Eder SE, Moore, K, Shangold G. A novel, oral tranexamic acid formulation for heavy menstrual bleeding: effect on quality of life. In: Papers on current clinical and basic investigation. San Francisco, CA: American College of Obstetricians and Gynecologists; Tuesday, May 18, 2010. Abstract 33. Accessed September 8, 2010.

(2.) Muse KN, Rubin A, Hecht B, Archer DE Neither age nor fibroids "affect response to menorrhagia treated with a novel, oral tranexamic acid. In: Poster sessions. San Francisco, CA: American College of Obstetricians and Gynecologists; Tuesday, May 18, 2010. Poster 36 postersTue.pdf. Accessed September 8, 2010.

(3.) Rybo G. Tranexamic acid therapy: effective treatment in heavy menstrual bleeding. Clinical update on safety. Therapeutic Adv. 1991;4:1-8.

(4.) Berntorp E, Follrud C, Lethagen S. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb Haemost. 2001;86(2):714-715.

(5.) Kouides PA, Byams VR, Phllipp CS, et al. Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Brit J Haematol. 2009;145(2):212-200.

(6.) Novikova N, Hofmeyr GJ. Tranexamic acid for preventing postpartum hemorrhage. Cochrane Database Syst Rev. 2010;7:CD007872.

(7.) Shakur H, Elbourne D, Gulmezoglu M, et al. The WOMAN trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum hemorrhage: an international randomised, double blind placebo controlled trial. Trials. 2010; 11:40.

Robert L. Barbieri, MD Editor in Chief



Dr. Barbieri reports no financial relationships relevant to this article.
COPYRIGHT 2010 Quadrant Healthcom, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Editorial; over the counter
Author:Barbieri, Robert L.
Publication:OBG Management
Geographic Code:1USA
Date:Oct 1, 2010
Previous Article:Severe pain and burns during biopsy and genital wart removal .
Next Article:Cost is a deterrent to IUD use.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters